Hyperion DeFi (HYPD) Registration Filing summary

Company overview and business model

• Operates as a digital ophthalmic technology company and is the first U.S. public company building a strategic treasury of Hyperliquid's native token, HYPE, providing shareholders exposure to the Hyperliquid blockchain ecosystem.

• Develops the Optejet UFD, a proprietary ophthalmic liquid delivery device, targeting improved compliance and outcomes in eye care.

• Engages in onchain activities, including running a co-branded validator (Kinetiq x Hyperion) and deploying HYPE for staking and DeFi strategies.

Financial performance and metrics

• As of June 30, 2025, held $7.5 million in cash and cash equivalents and had an accumulated deficit of $207.5 million.

• Owed $8.2 million in principal and accrued interest under its Loan and Security Agreement as of June 30, 2025.

• Raised $50 million gross ($45 million net) in a June 2025 private placement, using all proceeds to purchase HYPE tokens.

• Purchased an additional $10.5 million of HYPE post-placement, totaling $55.5 million in HYPE acquisitions to date.

Use of proceeds and capital allocation

• Proceeds from warrant exercises (up to $107.4 million if fully exercised) would be used for working capital, general corporate purposes, and to build the HYPE token reserve.

• All proceeds from the June 2025 private placement were used to acquire HYPE tokens for the company's treasury.

• Future capital raises are planned to further expand the HYPE reserve, subject to market conditions.